Global Parkinson’s Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

November 2017 | 210 pages | ID: GD97E1104D8EN
Precision Business Insights (PBI)

Abstracts

Global Parkinson’s Treatment Market:

Global parkinson’s treatment market estimated to be valued US$ XX Mn in 2017 and poised to grow at CAGR of XX% over 2017-2023. Market forparkinson’s treatment is projected to reach US$ XX Mn by 2023.

Parkinson’s disease is the chronic, progressive neurodegenerative disorder that is characterized by rigidity, tremors, postural instability and bradykinesia (slowness of movement) and patients will also experience the significant non-motor symptoms like changes in the sleep disturbances, autonomic dysfunction and cognition and mood. The condition is caused due to the degeneration of the dopamine-producing cells of the substantia nigra. Parkinson’s disease is non-fatal but it cannot be cured, that results in the poor quality of life and increases disability along with the disease progression. As per the World Health Organization, the total number of people with disability-adjusted life year because of Parkinson’s disease was 1.7 Mn globally in 2015.

Recent advancements in the treatment of Parkinson’s disease like the combination or multiple therapies in order to prolong the actions of the continuous stimulation of dopaminergic drugs, neurostimulation devices approvals, neuroprotective therapies which slows the prognosis of Parkinson’s disease are anticipated to drive Parkinson’s disease treatment market globally.Furthermore, increase in ageing of the population, a rise in the Parkinsonism prevalence around the globe, treatment affordability are the factors bolstering the demand for some of the Parkinson’s disease treatment market. Factors such as loss of patent protection for some of the drugs, rise in competition from generic drugs of Parkinsonism, huge unmet needs in the market, delaying development and launch of new products in the market are the few restraints for the Parkinson’s disease treatment market growth. High competition in the market from other improved Parkinson’s disease management methods also hinders the growth of the Parkinson’s Treatment Market.

The global Parkinson’s Treatment Market has been classified on the basis of treatment, end user, and geography.

Based on drug class, global Parkinson’s Treatment Market is segmented into the following:

• Monoamine Oxidase Inhibitors (MAO)
• Dopamine Precursors
• Catechol-o-methyltransferase Inhibitors (COMT)
• Peripheral Decarboxylase Inhibitors
• Others (Anticholinergics, Antihistaminics)

Based on distribution channel, global Parkinson’s Treatment Market segmented as:

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
• Drug Stores

Parkinson’s disease is predominantly treated by mature and long-standing therapies like dopamine agonists and levodopa, hence, generic medicines are dominating the market. Adipose-derived stem cell therapy, Repetitive transcranial magnetic stimulation device, and minimally invasive neurostimulation devices, among others, are the new advancements in the Parkinson’s treatment. Healthcare professionals are adapting to the advancements in technologies that will offer better treatment quality when compared to conventional treatment and devices like stereotactic systems and ultrasonic aspirators. Drug manufacturers are introducing novel options for the treatment with the clear defined position in a market, specifically as the option in a reduction of motor fluctuations alongside levodopa therapy. Acquisitions, new product launches and Collaboration agreements are few strategies which were adopted by key players. For instance, in 2015 January, Neuropore Therapies Inc. entered into a commercialization agreement with UCB S.A, for commercialization of NPT200-11, a small molecule drug used to treat the Parkinson’s disease.

Geographically, the global Parkinson’s Treatment Market is segmented into five regions namely, Latin America, North America, Asia-Pacific, Europe, and the Middle East and Africa. North America dominates the global market for Parkinson’s disease treatment owing to the good reimbursement policies and high prevalence of the disease. As per the Parkinson’s disease Foundation, approximately every year 60,000 Americans were diagnosed with Parkinson’s disease. Europe is anticipated to hold the 2nd highest market share in the global market due to the increase in R&D investments by major players, growing disability-adjusted life years is driving the growth of the European Parkinson’s Treatment Market. As per the European Parkinson’s Disease Association, the disease treatment cost in Europe was estimated at US$ 12.6 Mn in 2015 and is expected to double by 2030. Rising prevalence of the disease and increasing demand for new drug therapies are the key drivers of the market. About 6.3 million people suffer from Parkinson’s disease according to the European Brain Council.

Some of the players in global Parkinson’s Treatment Market include Salix Pharmaceuticals (U.S.), GlaxoSmithKline Plc. (U.K.), Wockhardt Limited (India), Impax Laboratories, Inc. (U.S), Novartis AG (Switzerland), Mylan N.V (U.S), Teva Pharmaceutical Industries Ltd.(Israel), Cipla Inc.(India), Par Pharmaceutical (U.S), and Apotex Inc (Canada)

In 2015, U.S.FDA approved RYTARY an extended-release oral capsule of carbidopa and levodopa belongs to the Impax Laboratories, Inc., to treat Parkinson's disease and its complications

In 2012, Neupro (Rotigotine Transdermal System) of UCB has received USFDA approval which is for the treatment of advanced stage of idiopathic Parkinson's disease

REPORT OUTLINE:

• The report provides granular level information about the market size, regional market share and forecast from 2017-2023
• The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
• The Report Outlines drivers, restraints, challenges, and trends that are currently faced by the industry
• The report tracks recent innovations, key developments and startup’s details that are working in the industry
• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL PARKINSON’S TREATMENT MARKET INTRODUCTION

2.1. Global Parkinson’s Treatment Market– Taxonomy
2.2. Global Parkinson’s Treatment Market–Definitions
  2.2.1. Drug Class
  2.2.2. Distribution Channel

3. GLOBAL PARKINSON’S TREATMENT MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Parkinson’s Treatment Market Dynamics – Factors Impact Analysis
3.6. Global Parkinson’s Treatment Market– Regulations
  3.6.1. U.S
  3.6.2. Europe
  3.6.3. Japan

4. GLOBAL PARKINSON’S TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL PARKINSON’S TREATMENT MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Monoamine Oxidase Inhibitors (MAO)
  5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.1.3. Market Opportunity Analysis
5.2. Dopamine Precursors
  5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.2.3. Market Opportunity Analysis
5.3. Catechol-o-methyltransferase Inhibitors (COMT)
  5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.3.3. Market Opportunity Analysis
5.4. Peripheral Decarboxylase Inhibitors
  5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.4.3. Market Opportunity Analysis
5.5. Others (Anticholinergics, Antihistamines)
  5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.5.3. Market Opportunity Analysis

6. GLOBAL PARKINSON’S TREATMENT MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Hospital Pharmacies
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.1.3. Market Opportunity Analysis
6.2. Retail Pharmacies
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.2.3. Market Opportunity Analysis
6.3. Online Pharmacies
  6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.3.3. Market Opportunity Analysis

7. GLOBAL PARKINSON’S TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. North America
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.1.3. Market Opportunity Analysis
7.2. Europe
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
  7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.3.3. Market Opportunity Analysis
7.4. Latin America
  7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
  7.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.5.3. Market Opportunity Analysis
7.6. Global Parkinson’s Treatment Market- Opportunity Analysis Index - By Drug Class, By Distribution Channel, and Region, 2017 – 2023

8. NORTH AMERICA PARKINSON’S TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  8.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    8.1.1.1. Monoamine Oxidase Inhibitors (MAO)
    8.1.1.2. Dopamine Precursors
    8.1.1.3. Catechol-o-methyltransferase Inhibitors (COMT)
    8.1.1.4. Peripheral Decarboxylase Inhibitors
    8.1.1.5. Others (Anticholinergics, Antihistaminics)
  8.1.2. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    8.1.2.1. Hospital Pharmacies
    8.1.2.2. Retail Pharmacies
    8.1.2.3. Online Pharmacies
  8.1.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
    8.1.3.1. U.S.
    8.1.3.2. Canada
  8.1.4. North America Parkinson’s Treatment Market- Opportunity Analysis Index - By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
  8.1.5. North America Parkinson’s Treatment Market Dynamics – Trends

9. EUROPE PARKINSON’S TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  9.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    9.1.1.1. Monoamine Oxidase Inhibitors (MAO)
    9.1.1.2. Dopamine Precursors
    9.1.1.3. Catechol-o-methyltransferase Inhibitors (COMT)
    9.1.1.4. Peripheral Decarboxylase Inhibitors
    9.1.1.5. Others (Anticholinergics, Antihistaminics)
  9.1.2. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    9.1.2.1. Hospital Pharmacies
    9.1.2.2. Retail Pharmacies
    9.1.2.3. Online Pharmacies
  9.1.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    9.1.3.1. Germany
    9.1.3.2. UK
    9.1.3.3. France
    9.1.3.4. Spain
    9.1.3.5. Italy
    9.1.3.6. Russia
    9.1.3.7. Poland
    9.1.3.8. Rest of Europe
  9.1.4. Europe Parkinson’s Treatment Market- Opportunity Analysis Index - By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
  9.1.5. Europe Parkinson’s Treatment Market Dynamics – Trends

10. ASIA-PACIFIC PARKINSON’S TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  10.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    10.1.1.1. Monoamine Oxidase Inhibitors (MAO)
    10.1.1.2. Dopamine Precursors
    10.1.1.3. Catechol-o-methyltransferase Inhibitors (COMT)
    10.1.1.4. Peripheral Decarboxylase Inhibitors
    10.1.1.5. Others (Anticholinergics, Antihistaminics)
  10.1.2. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.2.1. Hospital Pharmacies
    10.1.2.2. Retail Pharmacies
    10.1.2.3. Online Pharmacies
  10.1.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
    10.1.3.1. Japan
    10.1.3.2. China
    10.1.3.3. India
    10.1.3.4. ASEAN
    10.1.3.5. Australia & New Zealand
    10.1.3.6. Rest of Asia-Pacific
  10.1.4. Asia-Pacific Parkinson’s Treatment Market- Opportunity Analysis Index - By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
  10.1.5. Asia-Pacific Parkinson’s Treatment Market Dynamics – Trends

11. LATIN AMERICA PARKINSON’S TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  11.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    11.1.1.1. Monoamine Oxidase Inhibitors (MAO)
    11.1.1.2. Dopamine Precursors
    11.1.1.3. Catechol-o-methyltransferase Inhibitors (COMT)
    11.1.1.4. Peripheral Decarboxylase Inhibitors
    11.1.1.5. Others (Anticholinergics, Antihistaminics)
  11.1.2. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.2.1. Hospital Pharmacies
    11.1.2.2. Retail Pharmacies
    11.1.2.3. Online Pharmacies
  11.1.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.3.1. Brazil
    11.1.3.2. Mexico
    11.1.3.3. Argentina
    11.1.3.4. Venezuela
    11.1.3.5. Rest of Latin America
  11.1.4. Latin America Parkinson’s Treatment Market- Opportunity Analysis Index - By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
  11.1.5. Latin America Parkinson’s Treatment Market Dynamics – Trends

12. MIDDLE EAST & AFRICA PARKINSON’S TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  12.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    12.1.1.1. Monoamine Oxidase Inhibitors (MAO)
    12.1.1.2. Dopamine Precursors
    12.1.1.3. Catechol-o-methyltransferase Inhibitors (COMT)
    12.1.1.4. Peripheral Decarboxylase Inhibitors
    12.1.1.5. Others (Anticholinergics, Antihistaminics)
  12.1.2. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.2.1. Hospital Pharmacies
    12.1.2.2. Retail Pharmacies
    12.1.2.3. Online Pharmacies
  12.1.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    12.1.3.1. Gulf Cooperation Council (GCC) Countries
    12.1.3.2. Israel
    12.1.3.3. South Africa
    12.1.3.4. Rest of MEA
  12.1.4. MEA Parkinson’s Treatment Market- Opportunity Analysis Index - By Drug Class, By Surgery, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
  12.1.5. MEA Parkinson’s Treatment Market Dynamics – Trends

13. COMPETITION LANDSCAPE

13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Drug & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  13.2.1. Salix Pharmaceuticals (U.S.)
  13.2.2. GlaxoSmithKline Plc. (U.K.)
  13.2.3. Wockhardt Limited (India)
  13.2.4. Impax Laboratories, Inc. (U.S)
  13.2.5. Novartis AG (Switzerland)
  13.2.6. Mylan N.V (U.S)
  13.2.7. Teva Pharmaceutical Industries Ltd.(Israel)
  13.2.8. Cipla Inc.(India)
  13.2.9. Par Pharmaceutical (U.S)
  13.2.10. Apotex Inc (Canada)

14. RESEARCH METHODOLOGY

15. KEY ASSUMPTIONS AND ACRONYMS